Ted Fish
Interventional Cardiology · Fayetteville, ARNPI 1053375857
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 159 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,739 and has fallen 98.6% since, to $24 in 2025. That places this record below the midpoint for interventional cardiology clinicians in AR, where the typical reported total is $7,561.
Across 159 payments — averaging $13.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$357
- Novartis$316
- Pfizer$213
- Johnson & Johnson$205
- AstraZeneca$193
- Amarin Pharma, Inc.$184
- plus $714 from 18 others
What the payments were for
- Food & beverage$2,16799%
- Education$151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 27 | $357 |
| Novartis | 22 | $316 |
| Pfizer | 19 | $213 |
| Johnson & Johnson | 17 | $205 |
| AstraZeneca | 13 | $193 |
| Amarin Pharma, Inc. | 11 | $184 |
| Sanofi-aventis U.S. LLC | 11 | $161 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $88 |
| Regeneron Healthcare Solutions, Inc. | 5 | $65 |
| Boehringer Ingelheim | 5 | $60 |
| Irhythm Technologies, Inc. | 3 | $44 |
| Lundbeck LLC | 3 | $40 |
| Boston Scientific | 1 | $33 |
| Astellas Pharma US Inc | 2 | $29 |
| Bardy Diagnostics, Inc. | 2 | $27 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| Abbott | 1 | $24 |
| Kowa Pharmaceuticals America, Inc. | 2 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Merck | 1 | $17 |
| Vifor Pharma, Inc. | 1 | $15 |
| Chiesi USA, Inc. | 1 | $14 |
| Bayer | 1 | $14 |
| Gilead | 1 | $11 |
How this compares
$2,182 in reported general payments places this provider in the 15th percentile of 89 interventional cardiology providers in Arkansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 12 | $91 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Fayetteville
- Zubair AhmedFayetteville$36K
- Salik NazirFayetteville$19K
- Shaun SenterFayetteville$8K
- Joel CarverFayetteville$5K
- Gaurav DharLittle Rock$206K
- Ernesto Ruiz-RodriguezLittle Rock$153K
- Vasili LendelLittle Rock$86K
- Thomas WattsLittle Rock$68K
- Vijay RajaLittle Rock$46K
- Lena AwarJonesboro$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.